|Bid||94.80 x 200|
|Ask||95.05 x 100|
|Day's range||94.45 - 95.70|
|52-week range||67.95 - 116.35|
|PE ratio (TTM)||N/A|
|Earnings date||7 Aug 2017 - 11 Aug 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||113.60|
Penumbra, Inc. , a global healthcare company focused on innovative therapies, today announced key events at the upcoming International Stroke Conference 2018 meeting to be held January 24-26 at the Los Angeles Convention Center.
The results of the independent, prospective, randomized controlled COMPASS Trial (A Comparison of Direct Aspiration vs. Stent Retriever as a First Approach) will be presented by J. Mocco, M.D., M.S., Ichan School of Medicine at Mount Sinai, New York. The multi-center COMPASS Trial compared mechanical thrombectomy with the ADAPT (A Direct Aspiration First Pass Technique) approach to stent retrievers in patients presenting with acute ischemic stroke (AIS) within six hours of symptom onset.
Penumbra's (PEN) joint venture with Sixense Enterprises indicates formation of a leading digital health platform in the field of virtual reality technology.
Penumbra, Inc. , a global healthcare company focused on innovative therapies, today announced it has entered into a joint venture called MVI Health Inc., for the purpose of exploring healthcare applications of virtual reality technology with Sixense Enterprises, Inc.
NEW YORK, NY, Jan. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Conn's, Inc. (NASDAQ:CONN), Molina Healthcare Inc (NYSE:MOH), Zillow Group, Inc. (NASDAQ:Z), Boston Properties, Inc. (NYSE:BXP), BWX Technologies, Inc. (NYSE:BWXT), and Penumbra, Inc. (NYSE:PEN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Jim Cramer examined the dip in shares of Penumbra, a medical device maker focused on treating strokes and aneurysms by removing blood clots.